Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 180 Life Sciences Corp ATNF

Technology Information Technology Services
180 Life Sciences Corp. is a clinical-stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation and fibrosis. The Company is primary focused on program to treat several inflammatory disorders using anti-TNF (tumor necrosis factor). The Company has three product development platforms: Anti-TNF platform, SCAs platform and a7nAChR... see more

Recent & Breaking News (NDAQ:ATNF)

180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite

GlobeNewswire July 31, 2023

180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement

GlobeNewswire April 10, 2023

180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement

GlobeNewswire April 5, 2023

180 Life Sciences Announces Presentation at the Gordon Conference

GlobeNewswire February 27, 2023

180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytren's Disease Treatment and Application

GlobeNewswire February 23, 2023

180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial

GlobeNewswire February 22, 2023

180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytren's Disease

GlobeNewswire January 25, 2023

180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom

GlobeNewswire January 17, 2023

Newman Ferrara LLP Investigating Officers and Directors of 180 Life Sciences Corp. (ATNF)

Business Wire January 10, 2023

180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire January 5, 2023

180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytren's Disease

GlobeNewswire January 4, 2023

180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders

GlobeNewswire December 29, 2022

180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire December 23, 2022

180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

GlobeNewswire December 20, 2022

180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan

GlobeNewswire December 16, 2022

180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytren's Contracture

GlobeNewswire November 30, 2022

180 Life Sciences to Participate in A.G.P.'s Virtual Biotech Conference to be Held November 30 - December 1, 2022

GlobeNewswire November 21, 2022

CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren's Disease

GlobeNewswire November 15, 2022

Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytren's Disease

GlobeNewswire November 15, 2022

180 Life Sciences Issues Letter to Stockholders

GlobeNewswire September 26, 2022